Perrigo Co. (Nasdaq: PRGO) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB’s Xyzal Oral Solution.
Allegan-based Perrigo Co. Tuesday announced that its partner, PharmaForce-Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05 percent, a generic version of Elestat.
The generic prescription and over-the-counter drug and health products manufacturer Perrigo Co. Thursday reported record revenue of $725 million for the quarter ended Sept. 24, up 13 percent from a year earlier.
Perrigo Co. announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for olopatadine hydrochloride nasal spray, sold by Alcon Laboratories as Patanase, an allergy drug.
Allegan-based Perrigo Co. announced that it has closed the acquisition of Paddock Laboratories Inc., a privately held, Minneapolis-based pharmaceutical manufacturer of generic prescription pharmaceuticals and over-the-counter specialty products for approximately $540 million in cash.
Allegan-based Perrigo Co. (Nasdaq: PRGO) Wednesday announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), previously Barr Laboratories Inc., has begun shipping Triamcinolone Acetonide Nasal Spray. Perrigo’s partner Teva was the first applicant to […]
Detroit-based Caraco Pharmaceutical Laboratories Inc. will shortly cease operation as a publicly traded company.
Allegan-based Perrigo Co. (Nasdaq: PRGO) and its partner Synthon Pharmaceuticals Inc. said Wednesday that they had received tentative approval from the U.S. Food and Drug Administration for an abbreviated new drug application for Levocetirizine Solution, […]
The Allegan generic drug and health and beauty supplies maker Perrigo Co. (Nasdaq: PRGO) reported record revenue of $691.6 million in its third fiscal quarter ended March 26, up from $537.6 million in the same quarter a year earlier. Net income was $91.5 million or 98 cents a share, up from $61.5 million or 66 cents a share in the same quarter of the prior fiscal year.
Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) said Tuesday that it had entered into a merger agreement Monday with Sun Pharmaceutical Industires Ltd., an Indian pharma firm that already owns 75.8 percent of Caraco’s stock.